Erectile dysfunction (ED) is inconvenient enough on its own. The last thing you want is a pile-on of other inconveniences, like having to go to a doctor’s office for a diagnosis and prescription — and ...
The Complaint alleges that Hims & Hers made materially false and misleading statements and failed to disclose material facts about its partnership with Novo Nordisk between April 29, 2025, and June 23 ...
Hims & Hers reported 2.4 million subscribers in Q1 FY25, a 38% YoY increase from 1.74 million in Q1 FY24. Personalized treatments now make up 58% of the subscriber base, with 70% of new users choosing ...
Hims & Hers Health (HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS stock has rallied 171% year-to-date, as investors are ...
NEWTOWN, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Hims & Hers Health, Inc. (“Hims”) (NYSE: HIMS), ...
Hims & Hers Health, Inc. (HIMS) shares soared 23% in the last trading session to close at $35.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Hims & Hers Health, LifeMD, Ro, and other platforms like them will now be able to sell Novo Nordisk's Wegovy, which is used for weight loss. The blockbuster GLP-1 should entice customers. Shares ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback